Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
| Ticker |
Sentiment |
Impact |
|
FOLD
|
Neutral
|
14 %
|
|
EXEL
|
Neutral
|
14 %
|
|
GILD
|
Somewhat Bullish
|
17 %
|
|
GSK
|
Somewhat Bullish
|
10 %
|
